Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: A propensity matched analysis

Joshua S. Jue, Tulay Koru-Sengul, Feng Miao, María C. Velásquez, Luís F. Sávio, Mahmoud Alameddine, Zachary A. Kroeger, Sanoj Punnen, Dipen J. Parekh, Chad R. Ritch, Mark L. Gonzalgo

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background: We compared survival outcomes among patients who received either NAC or AC and RC. Methods: We identified patients in the National Cancer Data Base (NCDB) diagnosed with clinical T2-T4, N0, M0 urothelial carcinoma who underwent RC. Patients who received NAC were propensity matched by age, race, ethnicity, sex, insurance type, academic/research program, comorbidity, and clinical stage to patients receiving AC within 90 days of RC. Median survival was calculated using Kaplan-Meier analysis. Adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) were calculated from multivariable Cox regression models to compare overall survival (OS), downstaging to non-MIBC (NMIBC), and N upstaging. Results: A total of 417 patients treated with NAC and 272 patients treated with AC were identified from 2004-2013. Patients who received NAC had better 5-year OS (46.2%, 95% CI: 39.2-53.0%) compared to patients who received AC (37.6%, 95% CI: 31.5-43.7%). NAC was a significant predictor of decreased mortality, decreased progression to node positivity, and downstaging to NMIBC (0.76, 0.60-0.96, P=0.023; 0.19, 0.13-0.28, P<0.001; 23.96, 8.91-64.42, P<0.001). Conclusions: The use of NAC+RC was associated with improved OS compared to RC+AC for patients diagnosed with T2-T4, N0, M0 bladder cancer. The increased survival benefit associated with NAC compared to AC among patients undergoing RC may be due to decreased progression to node positivity and pathological downstaging.

Original languageEnglish (US)
Pages (from-to)572-580
Number of pages9
JournalMinerva Urology and Nephrology
Issue number5
StatePublished - Oct 2021
Externally publishedYes


  • Chemotherapy, adjuvant
  • Cystectomy
  • Neoadjuvant therapy

ASJC Scopus subject areas

  • Nephrology
  • Urology
  • Medicine(all)


Dive into the research topics of 'Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: A propensity matched analysis'. Together they form a unique fingerprint.

Cite this